Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
|Articles|December 31, 2006
Recurring Ingrown Toenail: How to Avoid
After I have treated patients for ingrowntoenail, I suggest that they preventrecurrences by regularly filingthe central portion of the nail to keepit thin.
Advertisement
After I have treated patients for ingrowntoenail, I suggest that they preventrecurrences by regularly filingthe central portion of the nail to keepit thin. The nail will then begin togrow more toward the center, insteadof the sides, to compensate for theloss of thickness.
-- Adriana Pavletic, MD
Omaha
Advertisement
Related to this article
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
Advertisement
Advertisement
Trending on Patient Care Online
1
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
Elinzanetant for Menopause-Related VMS: Onset of Relief and Adverse Effects
4
Menopause Hormone Therapy Gaps Raise Questions for Primary Care
5